




Unmet Needs in Agitation Associated with Alzheimer's Dementia (AAD)

This program is paid for by Otsuka
Pharmaceutical Development &
Commercialization, Inc. (OPDC) and
Lundbeck, LLC.

Alzheimer's Dementia (AD) Is Highly Prevalent and Predicted to Increase Significantly¹



1. 2022 Alzheimer's Disease Facts and Figures. *Alzheimer's Dement.* 2022;18(4):700-789.

Neuropsychiatric Symptoms (NPS) Like Agitation Are Core Features of AD¹



In addition to cognitive decline, manifestations of AD include a range of NPS, such as depression, anxiety, irritability, and **agitation**^{1,2}



Agitation is one of the most **complex, prominent, stressful, and costly** aspects of AD care^{2,3}

1. Anatchkova M, et al. *Int Psychogeriatr*. 2019;31(9):1305-1318.
2. Kales HC, et al. *BMJ*. 2015;350:h369.
3. Antonsdottir IM, et al. *Expert Opin Pharmacother*. 2015;16(11):1649-1656.

Summary of NSD Monoamine Dysfunction in AAD


Tau pathology and neurodegeneration in key prefrontal and subcortical brain regions may increase the risk of developing AAD¹

AAD may reflect an imbalance between top-down **executive control** and bottom-up **emotional drive**¹

Dysfunction of NSD neurotransmitter system may contribute to imbalance between **executive control** and **emotional override**²⁻¹⁰

↓ PFC function²
(**executive control**)

↑ Amygdala function³
(**emotional drive**)



Norepinephrine system

Overactivity⁴

Serotonin system

Deficits⁶

Dopamine system

Dysregulation⁹

LC=locus coeruleus. NSD=norepinephrine, serotonin, dopamine. PFC=prefrontal cortex. RN=raphe nuclei. SN=substantia nigra. VTA=ventral tegmental area.

1. Rosenberg PB, et al. *Mol Aspects Med.* 2015;43-44:25-37.
2. Banno K, et al. *Neuropsychiatr Dis Treat.* 2014;10:339-348.
3. Wright CI, et al. *Biol Psychiatry.* 2007;62(12):1388-1395.
4. Jacobs HI, et al. *Mol Psychiatry.* 2021;26(3):897-906.

5. Arnsten AF, et al. *Neurobiol Stress.* 2015;1:89-99.
6. Lancôt KL, et al. *J Neuropsychiatry Clin Neurosci.* 2001;13(1):5-21.
7. Evers EA, et al. *Curr Pharm Des.* 2010;16(18):1998-2011.
8. Duke AA, et al. *Psychol Bull.* 2013;139(5):1148.
9. Cox SM, et al. *Br J Psychiatry.* 2011;199(5):391-397.
10. Lindenmayer JP. *J Clin Psychiatry.* 2000;61(14):5-10.

The International Psychogeriatric Association (IPA) Definition of Agitation in Patients With Cognitive Disorders¹

The consensus definition for agitation in cognitive disorders includes four criteria:

1. The patient meets the criteria for cognitive impairment or dementia syndrome
2. The patient must exhibit ≥ 1 agitation behavior(s), and the behavior(s) must be persistent or frequently recurrent for ≥ 2 weeks
3. The agitation must be severe enough to produce excess disability beyond that due to cognitive impairment
4. The agitation cannot be attributed to another psychiatric disorder, suboptimal care conditions, a medical condition, or the physiological effects of substance use.

Agitation behaviors include:



Excessive motor activity behaviors:

- Pacing
- Rocking
- Gesturing
- Pointing fingers
- Restlessness
- Performing repetitious mannerisms



Verbal aggression behaviors:

- Yelling
- Speaking in an excessively loud voice
- Using profanity
- Screaming
- Shouting




Physical aggression behaviors:

- Grabbing
- Shoving
- Pushing
- Resisting
- Hitting others
- Kicking objects or people
- Scratching
- Biting
- Throwing objects
- Hitting self
- Slamming doors
- Tearing things
- Destroying property

The Cohen-Mansfield Agitation Inventory (CMAI) Measures the Frequency of a Broad Range of Agitated Behaviors

1. The CMAI questionnaire quantifies the frequency of 29 agitated behaviors within the previous two weeks, rated on a 7-point scale¹
2. The questionnaire can be completed by caregivers or healthcare practitioners^{1,2}
3. Point changes within the CMAI scale should be compared and interpreted with care¹



1. Cohen-Mansfield J. *Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI)*. The Research Institute of the Hebrew Home of Greater Washington; 1991.
2. Sano M, et al. *J Prev Alzheimers Dis*. 2018;5(2):98-102.

The CMAI Measures a Broad Range of Behaviors of Agitation Consistent With the IPA Consensus Definition of Agitation

- Many behaviors in the CMAI are relevant to the three domains of the IPA definition of agitation, including^{1,2}:



Excessive motor activity



Verbal aggression



Physical aggression


29 CMAI behaviors ^{2,3}				
Pacing and aimless wandering	Hiding things	Throwing things	Spitting	Making physical sexual advances or exposing genitals
Inappropriate dressing or disrobing	Hoarding things	Screaming	Cursing or verbal aggression	Eating or drinking inappropriate substances
Trying to get to a different place	Constant unwarranted request for attention and/or help	Biting	Hitting self or others	Making strange noises
Handling things inappropriately	Repetitive sentences and questions	Scratching	Kicking	Intentional falling
Performing repetitious mannerisms	Complaining	Hurting self or others	Grabbing people or things inappropriately	Making verbal sexual advances
General restlessness	Negativism	Tearing things or destroying property	Pushing	




1. Cummings J, et al. *Int Psychogeriatr*. 2015;27(1): 7-17.
 2. Cohen-Mansfield J. *Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI)* 1991.
 3. Rabinowitz J, et al. *Am J Geriatr Psychiatry*. 2005;13(11):991-998.

Agitation Associated with AD Is Highly Prevalent Across Patient Settings and Disease Severity^{1,2}

Patient Care Setting^{2,3}



AD Severity²



*Nursing home percentage reported includes those with AD and other dementias.

1. Kales H, et al. BMJ. 2015;350:h369.
2. Halpern R, et al. Int J Geriatr Psychiatry. 2019;34(3):420-431.
3. Fillit H, et al. Int J Geriatr Psychiatry. 2021;36(12):1959-1969.

AAD Worsens the Impact of an Already Devastating Disease for the Patient

AAD is associated with¹⁻⁵:



Accelerated disease progression



Increased risk of institutionalization



Functional decline



Earlier death



Decreased quality of life

1. Banerjee S, et al. *J Neurol Neurosurg Psychiatry*. 2006;77(2):146-148.
2. Halpern R, et al. *Int J Geriatr Psychiatry*. 2019;34(3):420-431.
3. Koenig AM, et al. *Curr Psychiatry Rep*. 2016;18(1):3.

4. Peters ME, et al. *Am J Psychiatry*. 2015;172(5):460-465.
5. Scarmeas N, et al. *Arch Neurol*. 2007;64(12):1755-1761.

Caregivers Are Needed to Identify Symptoms of AAD Despite Carrying a Substantial Burden Themselves¹⁻⁶

- Detection of agitation is often based on **caregiver report**⁵
 - **Underdiagnosis of AAD** may result from inadequate reporting by caregivers due to the burden involved in providing care^{5,6}
- Burden of care **increases with severity** of agitation¹⁻⁴
- Caregiver distress can lead to **increased institutionalization** of patients with dementia⁴
- Informal caregivers spend more than **20 additional hours per week** actively helping patients with agitation⁴

1. Allegri RF, et al. Neuropsychiatr Dis Treat. 2006;(1):105-110.

2. Grossberg GT, et al. Am J Geriatr Psychiatry. 2020;28(4):383-400.

3. Mohamed S, et al. Am J Geriatr Psychiatry. 2010;18(10):917-927.

4. Okura T, et al. Alzheimer Dis Assoc Disord. 2011;25(2):116-121.

5. Stella F, et al. Int J Geriatr Psychiatry. 2015;30(12):1230-1237.

6. Amjad H, et al. J Gen Intern Med. 2018;33(7):1131-11387.

Treatment Guidelines for Agitation Associated with Alzheimer's Disease^{1,2}



Differential diagnosis

Careful evaluation and treatment for general medical, psychiatric, environmental, or psychosocial problems that may underlie the disturbance



Nonpharmacological intervention

If agitation does not cause significant danger or marked distress to the patient or others, symptoms are best treated with environmental or behavioral measures



Pharmacological intervention

If nonpharmacological measures are unsuccessful or behaviors are dangerous or markedly distressing, then judicious pharmacological intervention is recommended

1. Rabins PV, et al. *Am J Psychiatry*. 2007;164(12):5-56.

2. Reus VI, et al. *Am J Psychiatry*. 2016;173(5):543-546.

Treatment Considerations



Currently, clinicians may prescribe the following¹⁻³:

- Antidepressants
- Anxiolytics or sedative-hypnotics
- Antipsychotics (typical and atypical)
- Other Medications

Pharmacological treatments for AAD can be associated with adverse events:^{2,5-7}



Sedation*



Extrapyramidal symptoms



Orthostatic hypotension



Cognitive worsening



Fractures and falls



Cerebrovascular and cardiovascular complications

*Some family caregivers of patients with Alzheimer's disease and other forms of dementia find sedative effects distressing and unhelpful⁷.

1. Aigbogun MS, et al. *J Alzheimers Dis.* 2020;77(3):1181-1194.

2. Schneider LS, et al. *Am J Geriatr Psychiatry.* 2006;14(3):191-210.

3. Rabins PV, et al. *Am J Psychiatry.* 2007;164(12):5-56.

4. Porsteinsson AP, et al. *JAMA.* 2014;311(7):682-691.

5. Caraci F, et al. *F1000Res.* 2020;9:F1000 Faculty Rev-686.

6. Marcinkowska M, et al. *CNS drugs.* 2020;34(3):243-268.

7. Harding R, et al. *Med Law Rev.* 2012;21(2):243-277.

There Is an Unmet Need for FDA-approved Treatments for AAD



There is a need for approved pharmaceutical treatments that demonstrate efficacy, in addition to safety, in the treatment of AAD

FDA=US Food and Drug Administration.

1. Caraci F, et al. *F1000Res*. 2020;9:F1000 Faculty Rev-686.


For more information or to request a more detailed live presentation on this topic from your local Clinical Science Liaison, please visit
www.PsychU.org/events

www.PsychU.org

Get Your Resources On The Go



Download the **PsychU App** from Google Play or from the Apple App Store!



Subscribe to **The PsychU Community Podcast** on the Google Podcasts app or on the Apple Podcasts app.

Connect with us on social media:





Unmet Needs in Agitation Associated with Alzheimer's Dementia (AAD)